IntroductionMumps data were analysed to assess the effect of vaccination on mumps complications and hospitalisation.MethodsThe mumps cases reported to the Czech nationwide surveillance system from 2013 to 2022 were analysed using logistic regression with an odds ratio (aOR) adjusted for age, sex, year of onset and administrative region to measure the association between vaccination and complications or hospitalisation. Adjusted vaccine effectiveness (aVE) was calculated: aVE=(1-aOR)x100.ResultsA total of 11,913 mumps cases were reported, of which 6,885 (58%) were male. The median age of the study participants was 16 (range: 0-89 years). No complications occurred in 91% of patients. Mumps orchitis occurred in 633 (9%) male cases. A total of 946 (8%) patients required hospitalisation. The highest proportion of complications and hospitalisations was in the age group 35-44 years. Two doses of vaccine reduced statistically significantly the risk of any complications and of hospitalisation compared with unvaccinated patients: aOR 0.48 (95% CI: 0.37, 0.62), aVE of 52% (95% CI: 38, 63); and aOR 0.43 (95% CI: 0.33, 0.56), aVE of 57% (95% CI: 44, 67), respectively. Two doses showed statistically significant aVE 50% (95% CI: 32, 64) against orchitis, and 59% (95% CI: 23, 79) against meningitis. Among the two-dose recipients, the proportion of complications increased gradually with the time from the second dose.ConclusionsOur findings demonstrated a protective effect of two-dose vaccination against mumps complications and hospitalisation for mumps. We recommend continuing routine childhood mumps vaccination and maintaining high MMR coverage in Czechia. UvodAnalizirali smo podatke o mumpsu, da bi ocenili u & ccaron;inek cepljenja na zaplete in hospitalizacijo zaradi mumpsa.MetodePrimere mumpsa, ki so bili v obdobju 2013-2022 prijavljeni v dr & zcaron;avni sistem nadzora na & Ccaron;e & scaron;kem, smo analizirali z logisti & ccaron;no regresijo z razmerjem obetov (aOR), prilagojeno glede na starost, spol, leto za & ccaron;etka in upravno regijo, da bi ugotovili povezavo med cepljenjem in zapleti ali hospitalizacijo. Izra & ccaron;unali smo prilagojeno u & ccaron;inkovitost cepiva (aVE): aVE = (1 - aOR) x 100.RezultatiSkupaj je bilo prijavljenih 11.913 primerov mumpsa, od tega 6885 (58 %) pri mo & scaron;kih. Povpre & ccaron;na starost udele & zcaron;encev v & scaron;tudiji je bila 16 let (razpon: 0-89 let). Pri 91 % bolnikov ni pri & scaron;lo do zapletov. Mumps orhitis se je pojavil pri 633 (9 %) mo & scaron;kih. Skupaj je 946 (8 %) bolnikov potrebovalo hospitalizacijo. Najve & ccaron;ji dele & zcaron; zapletov in hospitalizacij je bil v starostni skupini 35-44 let. Dva odmerka cepiva sta statisti & ccaron;no pomembno zmanj & scaron;ala tveganje za nastanek morebitnih zapletov in hospitalizacijo v primerjavi z necepljenimi bolniki: aOR 0,48 (95 % IZ: 0,37, 0,62), aVE 52 % (95 % IZ: 38, 63) in aOR 0,43 (95 % IZ: 0,33, 0,56), aVE 57 % (95 % IZ: 44, 67). Dva odmerka sta pokazala statisti & ccaron;no pomembno aVE 50 % (95 % IZ: 32, 64) v primerjavi z orhitisom in 59 % (95 % IZ: 23, 79) v primerjavi z meningitisom. Dele & zcaron; zapletov med prejemniki dveh odmerkov se je postopoma pove & ccaron;eval s & ccaron;asom od drugega odmerka.Zaklju & ccaron;kiNa & scaron;e ugotovitve so pokazale za & scaron;& ccaron;itni u & ccaron;inek cepljenja proti zapletom in hospitalizaciji zaradi mumpsa. Priporo & ccaron;amo nadaljevanje rutinskega cepljenja otrok proti mumpsu in ohranjanje visoke stopnje precepljenosti s cepivom OMR na & Ccaron;e & scaron;kem.
